|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrate in models of ovarian cancer, melanoma, and glioblastoma that infusions of nanoparticles formulated with mRNAs encoding interferon regulatory factor 5 in combination with its activating kinase IKKβ reverse the immunosuppressive, tumor-supporting state of TAMs and reprogram them to a phenotype that induces anti-tumor immunity and promotes tumor regression.
|
31481662 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor immune rejection has been previously linked to the activation of the interferon-stimulated genes (ISG) STAT1, IRF-5 and IRF-1.
|
28507795 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IRF5 is also a tumor suppressor, and its expression is dysregulated in several human cancers.
|
29079574 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of primary immune cell subsets revealed that IRF5 specifically recruits CXCR5(+) B and T cells to the tumor; CXCR5 is the receptor for CXCL13.
|
25533286 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IRF-5 participates in virus-induced TLR-mediated innate immune responses and may play a role as a tumor suppressor.
|
25557482 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our strategy efficiently identified a lymphoma type-specific key regulator and uncovered a tumor promoting role of IRF5.
|
25288773 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest that, in thyroid malignancies, IRF5 displays tumor-promoting rather than tumor-suppressor activities.
|
22507190 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results show that cryptic deletions, insertions and/or point mutations inactivating genes within 7q32 are not common in SMZL, and suggest that IRF5 may be a haploinsufficient tumour suppressor in this lymphoma entity.
|
22816737 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Since relationships have been observed between development of autoimmunity and responsiveness of melanoma to several types of immunotherapy, we tested whether polymorphisms of IRF5 are associated with responsiveness of melanoma to adoptive therapy with tumor infiltrating lymphocytes (TILs).
|
22909381 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IRF5 is an important tumor suppressor that regulates multiple cellular processes involved in the conversion of normal mammary epithelial cells to tumor epithelial cells with metastatic potential.
|
22053985 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of IRF-5 in this setting is surprising since IRF-5 has tumor suppressor and antiviral properties.
|
17609264 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Human IFN regulatory factor-5 (IRF-5) is a candidate tumor suppressor gene that mediates cell arrest, apoptosis, and immune activation.
|
16103093 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IRF-5 inhibits both in vitro and in vivo B-cell lymphoma tumor growth in the absence of wild-type p53.
|
14559832 |
2003 |